Is joint decision making crucial for prostate cancer patients?15 Sep 2016
A new research paper emphasizes the importance of joint decision making between prostate cancer patients and their physicians when weighing treatment options for early stage disease. Findings from the Prostate Testing for Cancer and Treatment (ProtecT) trial can help patients understand the full range of approaches to managing their disease, including the risks and benefits of active monitoring versus early treatment with radiation therapy (RT) or surgery.
The randomized trial included 2,664 men who volunteered to be a part of this study. The ten-year findings from the trial indicate that:
- For men with early stage prostate cancer, there is no difference in mortality rates following active monitoring, surgery or RT, and moreover, that cancer-specific deaths at ten years following diagnosis averaged only 1% for all men enrolled in the trial.
- The growth of cancer outside of the prostate did vary between monitoring and treatment groups.
- Rates of both regional spread and distant metastases were significantly higher for men who were monitored rather than treated for their early stage disease. Progression did not vary, however, between the surgery and RT groups, although patients in the trial reported different side effects with each modality.
The best treatment decisions for any cancer take into consideration the patient
"These findings underscore the essential role of dialogue in treatment selection," said the President of the American Society for Radiation Oncology (ASTRO) David C. Beyer, MD, FASTRO. "Men with prostate cancer are all different, and the relative costs and benefits associated with the multiple options to treat it can vary substantially between individuals. The best treatment decisions for prostate cancer, or any cancer, take into consideration the specifics of each individual patient's disease, expectations and preferences. These options can be confusing, and patients should always make these decisions after consultation with a radiation oncologist and urologist"
ASTRO, the American Urological Association (AUA) and the American Society for Clinical Oncology (ASCO) are currently developing updated guidelines for the management of clinically localized prostate cancer. The recommendations, which update a 2007 collaborative guideline issued by the societies, are scheduled for publication in mid-2017.
Source: Science Daily